Everyone in GLP-1 is reading the same shopper panels and the same pipeline trackers. That's exactly why so many category strategies look identical.

What 2026 is actually saying: I. Mounjaro grew 91% to $9.94B in one quarter. The Wegovy pill outsold Foundayo 5:1 in Q2. Oral GLP-1 is now a shelf war, not a pipeline story. II. CagriSema is under review, and retatrutide is heading to filing. Each one redraws the companion-nutrition brief. III. ~65% of one large US employer buying group now excludes obesity GLP-1s, while France started reimbursing in June. IV. Ozempic sentiment is 76% positive, yet one in five conversations is about side effects, muscle loss and "what happens when I stop." Translation: the next wave of value sits in protein density, fibre, GI tolerance, lean-mass support and green substitutes, and it moves faster than a level-3 category map can track. The teams pulling ahead aren't buying more reports. They're working from a 14-level GLP-1 universe map: 9,942 leaf-level categories, 553 named molecules and ingredients, and 664 USA and Europe companies. It runs from peptide API and CDMO capacity to precision-fermented whey, upcycled fibre and the "GLP-1 friendly" aisle, and 3,220 of those nodes are green substitutes alone. Each node is refreshed against live sentiment, filings and trial readouts, so commercial calls rest on today's data, not last year's. The map was built at Apex Metrics. Strategy and marketing heads who've seen it tend to ask one question: "Where are we missing?" Question for your team: how deep does your GLP-1 map go?